Mind the gap: Potential for rebounds during antiangiogenic treatment breaks

John M L Ebos, Roberto Pili

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

VEGF pathway inhibitors have shown benefits in many cancers, yet many (often controversial) questions remain about whether vascular and tumor regrowth can occur when therapy is stopped. Marked increases in endothelial cell proliferation could play a role in putative rebounds, potentially influencing overall efficacy, dosing schedules, and presurgical intervention strategies.

Original languageEnglish (US)
Pages (from-to)3719-3721
Number of pages3
JournalClinical Cancer Research
Volume18
Issue number14
DOIs
StatePublished - Jul 15 2012
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Blood Vessels
Neoplasms
Appointments and Schedules
Endothelial Cells
Cell Proliferation
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Mind the gap : Potential for rebounds during antiangiogenic treatment breaks. / Ebos, John M L; Pili, Roberto.

In: Clinical Cancer Research, Vol. 18, No. 14, 15.07.2012, p. 3719-3721.

Research output: Contribution to journalArticle

@article{356b0ad0a4424e9499bf66aef4541874,
title = "Mind the gap: Potential for rebounds during antiangiogenic treatment breaks",
abstract = "VEGF pathway inhibitors have shown benefits in many cancers, yet many (often controversial) questions remain about whether vascular and tumor regrowth can occur when therapy is stopped. Marked increases in endothelial cell proliferation could play a role in putative rebounds, potentially influencing overall efficacy, dosing schedules, and presurgical intervention strategies.",
author = "Ebos, {John M L} and Roberto Pili",
year = "2012",
month = "7",
day = "15",
doi = "10.1158/1078-0432.CCR-12-1459",
language = "English (US)",
volume = "18",
pages = "3719--3721",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "14",

}

TY - JOUR

T1 - Mind the gap

T2 - Potential for rebounds during antiangiogenic treatment breaks

AU - Ebos, John M L

AU - Pili, Roberto

PY - 2012/7/15

Y1 - 2012/7/15

N2 - VEGF pathway inhibitors have shown benefits in many cancers, yet many (often controversial) questions remain about whether vascular and tumor regrowth can occur when therapy is stopped. Marked increases in endothelial cell proliferation could play a role in putative rebounds, potentially influencing overall efficacy, dosing schedules, and presurgical intervention strategies.

AB - VEGF pathway inhibitors have shown benefits in many cancers, yet many (often controversial) questions remain about whether vascular and tumor regrowth can occur when therapy is stopped. Marked increases in endothelial cell proliferation could play a role in putative rebounds, potentially influencing overall efficacy, dosing schedules, and presurgical intervention strategies.

UR - http://www.scopus.com/inward/record.url?scp=84863889456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863889456&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-12-1459

DO - 10.1158/1078-0432.CCR-12-1459

M3 - Article

C2 - 22679177

AN - SCOPUS:84863889456

VL - 18

SP - 3719

EP - 3721

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 14

ER -